PANX1-mediated NLRP3 inflammasome activation promotes an adaptive doxorubicin resistance through IL-1β signaling in breast cancer - PubMed
4 hours ago
- #PANX1-NLRP3-IL1β
- #chemoresistance
- #breast-cancer
- PANX1-mediated NLRP3 inflammasome activation promotes doxorubicin resistance in breast cancer via IL-1β signaling.
- High PANX1 expression correlates with poor survival, genomic instability, and chemoresistance in breast cancer patients.
- Doxorubicin treatment triggers PANX1-dependent NLRP3 inflammasome activation and IL-1β maturation.
- Inhibition of PANX1 re-sensitizes resistant breast cancer cells to doxorubicin in vitro and in vivo.
- Exogenous IL-1β reverses the effect of PANX1 inhibition, identifying it as a key resistance effector.
- PANX1 and NLRP3 interaction predicts pathological complete response (pCR) in DOX-based neoadjuvant chemotherapy.
- PANX1 is a potential biomarker and therapeutic target for overcoming DOX resistance in breast cancer.